Summary of Recent Deal Activities
- PDF / 125,576 Bytes
- 13 Pages / 610 x 823 pts Page_size
- 1 Downloads / 221 Views
TECHNOLOGY DEALS
© 2003 Adis Data Information BV. All rights reserved.
Summary of Recent Deal Activities Drug Discovery Techonolgies Companies Allergan, Inc., ExonHit Therapeutics
Type of Deal R&D agreement
Bayer AG, Artemis Pharmaceuticals GmbH
Bayer HealthCare AG, ComGenex
R&D agreement
Bayer Pharmaceuticals Corporation, Dharmacon, Inc.
Supply agreement
Biogen, Inc., GlycoFi, Inc.
R&D agreement
© Adis Data Information BV 2003. All rights reserved.
Details In November 2003, Allergan, Inc. initiated high-throughput screening on a target generated by ExonHit Therapeutics, pursuant to a 10-month-old strategic alliance between the companies. ExonHit delivered to Allergan a small-molecule target that showed efficacy in a previously unrecognised pathway identified using DATAS, ExonHit’s proprietary gene-profiling technology. The strategic alliance was formed in December 2002 with the purpose of developing new drugs in the field of neurodegenerative diseases, pain and ophthalmology. The dual goals of the agreement are to identify new molecular targets based on the DATAS technology and to work collaboratively toward developing and commercialising compounds and commercial products based on these targets. In November 2003, Artemis Pharmaceuticals GmbH and Bayer AG signed a cooperation agreement in mouse genetics. As part of this cooperation, Artemis will use its ArteMice platform to generate genetically engineered mice for Bayer. Bayer will use these mice in its human drug-discovery research activities for gene function analysis as well as for the testing of drug candidates. ArteMice Conditional gene targeting and ArteMice Speed technologies allow the rapid and highly efficient generation of complex genetically modified mice. ArteMice, in which the mouse gene has been completely replaced by its human ortholog, has a particularly high level of similarity to human biology and therefore importance for drug discovery. They provide an optimal model for the early in vivo testing of lead compound toxicity and efficacy on the specific human target. In November 2003, Bayer HealthCare AG and ComGenex renewed their exclusive chemistry collaboration for the sixth consecutive year. During the extended term ComGenex will focus on further improving the overall properties of compound libraries by applying proprietary design criteria and extending chemical diversity. The potentially bioactive compound libraries will be used for applications in all discovery research areas of Bayer HealthCare’s pharma division. In November 2003, Dharmacon, Inc. agreed to supply custom short interfering RNA (siRNA) reagents to Bayer Pharmaceuticals Corporation. The siRNA reagents supplied to Bayer will be designed using Dharmacon’s proprietary SMARTselection and SMARTpool technologies and will be among the siRNAs used by Bayer in the company’s target validation research. In November 2003, GlycoFi, Inc. and Biogen, Inc. initiated a joint research study to evaluate GlycoFi’s humanised yeast platform for the production of an undisclosed Biogen protei
Data Loading...
